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Abstract
Background We sought to investigate the prognosis of patients following curative-intent surgery for intrahepatic
cholangiocarcinoma (ICC) stratified by hepatitis B (HBV-ICC), hepatolithiasis (Stone-ICC), and no identifiable
cause (conventional ICC) etiologic subtype.
Methods 986 patients with HBV-ICC (n = 201), stone-ICC (n = 103), and conventional ICC (n = 682) who
underwent curative-intent resection were identified from a multi-institutional database. Propensity score matching
(PSM) was used to mitigate residual bias.
Results HBV-ICC patients more often had cirrhosis, earlier stage tumors, a mass-forming lesion, well-to-moderate
tumor differentiation, and an R0 resection versus stone-ICC or conventional ICC patients. Five-year recurrence-free
survival among HBV-ICC and conventional ICC patients was 23.9 and 17.8%, respectively, versus a recurrence-free
of only 8.3% among patients with stone-ICC. Similarly, 5-year overall survival among patients with stone-ICC was
only 18.3% compared with 48.9 and 38.0% for patients with HBV-ICC and conventional ICC, respectively. On PSM,
patients with stone-ICC group had equivalent long-term outcomes as HBV-ICC patients. In contrast, on PSM, stone-
ICC patients had a median overall survival of only 18.0 months versus 44.0 months for patients with conventional
ICC. Median overall survival after intrahepatic-only recurrence among patients who had stone-ICC (6.0 months) was
worse than OS among HBV-ICC (13.0 months) or conventional ICC (12.0 months) (p = 0.006 and p = 0.082,
respectively).
Conclusions While HBV-ICC had a better prognosis on unadjusted analyses, these differences were mitigated on
PSM suggesting no stage-for-stage differences in outcomes compared with stone-ICC or conventional ICC. In
contrast, patients with stone-ICC had worse long-term outcomes. These data highlight the relative importance of ICC
etiology relative to established clinicopathological factors in the prognosis of patients with ICC.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary liver malignancy after hepatocellular
carcinoma (HCC), accounting for 10–15% of all primary
liver cancers [1, 2]. Although relatively rare, the incidence of
ICC is gradually increasing worldwide [2, 3]. The incidence
of ICC has a wide geographical variation and is less common
in the West versus East Asia where the incidence can be as
high as 71/100,000 [2, 4]. The reason for this varied inci-
dence may be due to differences in causative risk factors for
ICC among Western versus Eastern patients [5]. For exam-
ple, in the West, primary sclerosing cholangitis (PSC), pri-
mary biliary cirrhosis (PBC), and hepatitis C (HCV) are the
most common risk factors for ICC; in contrast, in Eastern
countries, hepatitis B (HBV), hepatolithiasis, as well as
hepatic parasite infection are the major causes of ICC
[2, 6–8]. Although an association among these risk factors
and ICC has been established by epidemiologic investiga-
tion, many cases of ICC develop in the absence of known
etiological factors [9, 10].
Surgical resection remains the only potentially curative
treatment for ICC, yet only 20–40% of patients with ICC are
potential surgical candidates [11–13]. Compared with a 5%
survival for inoperable patients, 5-year survival after cura-
tive resection of ICC ranges from 20 to 35% [14, 15]. Data on
prognosis following resection have focused on tumor-
specific factors such as lesion size and number, as well as
vascular invasion and lymph node status. In contrast, only a
handful of studies have investigated the relative impact of
ICC etiology on long-term survival following resection of
ICC, and these data conflict [16–21]. For example, HBV
infection has been reported to be a favorable prognostic
factor after hepatic resection of ICC in some studies, but not
others [16–21]. Similarly, patients with hepatolithiasis-re-
lated ICC have been reported to have worse outcomes
compared with patients who had non-hepatolithiasis-asso-
ciated ICC or HBV-ICC in some studies, but similar or even
favorable prognosis in other reports [16, 18, 22–24]. Previ-
ous reports have been limited, as all were single center
studies with a small number of patients. In addition, previous
studies were largely based on patients exclusively from
either the West or the East. As such, the objective of the
current study was to investigate the impact of ICC etiology
on the prognosis of patients following resection of ICC using
a large, multi-institutional, international database. In addi-
tion, we sought to define recurrence, as well as post-recur-
rence prognosis following curative-intent surgery stratified
by ICC etiology subtype.
Materials and methods
Study population and design
A multi-institutional database that included 15 major
hepatobiliary centers in the USA, Europe, Australia, and
Asia was utilized to identify 1036 patients who underwent
curative-intent hepatic resection for ICC from 1990 to
2016. The 15 medical centers included The Ohio State
University, Columbus, OH; Stanford University, Stanford,
CA; University of Virginia, Charlottesville, VA; Emory
University, Atlanta, GA; Fundeni Clinical Institute of
Digestive Disease, Bucharest, Romania; Johns Hopkins
Hospital, Baltimore, MD; Curry Cabral Hospital, Lisbon,
Portugal; Ospedale San Raffaele, Milan, Italy; Royal
Prince Alfred Hospital, University of Sydney, Sydney,
Australia; Eastern Hepatobiliary Surgery Hospital, Shang-
hai, China; Beaujon Hospital, Clichy, France; University of
Ottawa, Ottawa, Ontario, Canada; Erasmus University
Medical Centre, Rotterdam, Netherlands; University of
Verona, Verona, Italy; and Yokohama City University
School of Medicine, Yokohama, Japan. All patients were
diagnosed with ICC confirmed by histological examina-
tion. The Institutional Review Boards of each participating
institution approved the study.
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Based on the known causative factors of ICC, patients
were divided into HBV-associated ICC (HBV-ICC,
n = 201); hepatolithiasis-associated ICC (Stone-ICC,
n = 103); HCV-associated ICC (HCV-ICC, n = 15);
HBV ? HCV-ICC (n = 7); hepatitis ? stone-ICC
(n = 13); distomatosis hepatitis-associated ICC (fluke-
ICC, n = 15); and ICC with no attributable cause (con-
ventional ICC, n = 682). Due to the small number and
heterogeneity of patients with HCV-ICC, HBV ? HCV-
ICC, hepatitis ? stone-ICC, and fluke-ICC, these patients
were excluded (n = 50). In turn, 986 patients were inclu-
ded in the final analytic cohort stratified as HBV-ICC,
stone-ICC, and conventional ICC.
Data collection and follow-up
Standard demographic, perioperative clinicopathological,
and tumor-related characteristics were collected. Tumor
characteristics were based on final pathology reports
including liver cirrhosis, tumor size, tumor number, tumor
morphology, vascular/perineural/biliary/adjacent organ
invasion, lymph node metastasis, and histological grade.
Data on tumor stage were collected according to the
American Joint Committee on Cancer (AJCC) 7th edition
staging system [25].
After the initial operation, patients were regularly fol-
lowed with serum CA19-9, CEA, and abdominal CT or
MRI. Recurrence was defined as the presence of a biopsy-
proven tumor or an image showing a suspicious lesion.
Recurrence was classified as intrahepatic, extrahepatic, or
both intra- and extrahepatic. Recurrence time interval was
calculated from the date of the first surgery to the date of
recurrence. Overall survival (OS) and recurrence-free sur-
vival (RFS) were calculated from the date of surgery. OS
after the first recurrence was calculated from the date of
recurrence.
Treatment of recurrence
Patients with recurrence were evaluated for future treat-
ments based on tumor location, tumor number, general
performance status, and liver function. Curative-intent
therapies including surgical re-resection, ablation, or
combined resection plus ablation were considered for
patients with intrahepatic-only recurrence. Palliative treat-
ments such as intra-arterial therapies (IAT), chemotherapy,
and chemoradiation were considered for patients with
advanced recurrent disease. Patients with advanced recur-
rence, poor liver function, or severe medical comorbidities
received best supportive care (BSC).
Statistical analysis
Continuous variables were expressed as medians with
interquartile ranges (IQR) and compared with Mann–
Whitney U test or the Kruskal–Wallis test as appropriate.
Categorical variables were expressed as number and per-
centages and compared by Chi squared test or Fisher’s
exact test. OS and RFS rates were calculated by the
Kaplan–Meier method and compared using log-rank tests.
In all analyses, a two-tailed p value\0.05 was considered
statistically significant. Bonferroni correction was applied
for the comparison of clinical characteristics, recurrence
patterns and treatments, as well as OS and RFS among the
HBV-ICC, stone-ICC, and conventional ICC patients
(significance threshold, p = 0.05 divided by the number of
groups: p = 0.017). Propensity score matching (PSM) was
used to mitigate residual bias using variables potentially
affecting long-term outcomes in logistic regression analy-
sis. Propensity score analysis with 1:1 matching was per-
formed within a range of 0.05 of standard deviation.
Statistical analysis was carried out using SPSS 22.0 (Chi-
cago, IL, USA).
Results
Baseline characteristics
The clinicopathological characteristics of HBV-ICC
(n = 201, 20.4%), stone-ICC (n = 103,10.4%) and con-
ventional ICC (n = 682, 69.2%) patients are summarized
in Table 1. Patients with stone-ICC had similar clinic-
pathological characteristics as patients who had conven-
tional ICC with regard to age, gender, tumor features, type
of surgical procedure, as well as incidence of peri-operative
complications (all p[ 0.05). In contrast, patients with
HBV-ICC were more often male, younger, and had a
higher incidence of underlying hepatic cirrhosis (all
p\ 0.001). In addition, HBV-ICC patients were more
likely to have tumors characterized by favorable underly-
ing pathological features including smaller size, and dis-
ease that more often was solitary, unilobar, as well as well-
to-moderately differentiated (all p\ 0.01). HBV-ICC
patients were also less likely to undergo a major hepatec-
tomy and had lower intraoperative blood loss and
decreased perioperative morbidity (all p\ 0.01). HBV-
ICC patients had a higher incidence of an R0 resection
(HBV-ICC, 96.5%) than stone-ICC (80.6%) and conven-
tional ICC (85.3%) (p\ 0.001).
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Table 1 Clinicopathologic characteristics of curatively treated patients with intrahepatic cholangiocarcinoma associated with HBV infection,
hepatolithiasis, and unknown causes
HBV-ICC
(n = 201)
Stone-ICC
(n = 103)
Conventional ICC
(n = 682)
P value
Age (years) 52 (45–60) 61 (54–71) 61 (52–69) \0.001
Male gender 158 (78.6%) 51 (49.5%) 339 (49.7%) \0.001
Body mass index 24.3 (21.4–27.1) 24.5 (22.8–27.1) 25.6 (22.6–28.5) 0.001
Liver cirrhosis 74 (36.8%) 22 (21.4%) 9 (1.3%) \0.001
Clinical jaundice 5 (2.4%) 16 (15.5%) 79 (11.6%) \0.001
CA19-9 (U/mL) 27.3 (13.8–68.7) 93.0 (25.1–528.3) 73.0 (22.0–290.0) \0.001
CEA (ng/mL) 2.5 (1.6–4.0) 2.8 (1.5–5.1) 2.4 (1.4–4.4) 0.759
ALT (U/L) 28.8 (18.9–43.3) 33.0 (23.0–72.0) 30.0 (20.0–51.0) 0.044
AST (U/L) 28.0 (21.0–38.7) 33.0 (25.5–51.0) 32.0 (23.0–48.0) 0.002
TBIL (lmol/L) 12.0 (8.6–17.1) 12.0 (8.6–17.1) 12.0 (8.6–18.8) 0.997
Albumin (g/L) 41.9 (40.1–45.0) 39.8 (34.8–43.1) 41.3 (38.0–44.0) \0.001
Hemoglobin (g/L) 141.0 (129.0–150.0) 129.0 (113.7–139.3) 127.0 (116.0–138.0) \0.001
Platelet count (9109/L) 178.5 (132.0–224.5) 227.0 (177.0–296.5) 228.5 (179.0–289.3) \0.001
Tumor size (cm) 5.5 (3.8–7.6) 6.0 (3.5–8.8) 6.1 (4.5–9.0) 0.009
Multiple lesions (C2) 20 (10.0%) 21 (20.4%) 130 (19.1%) 0.008
Bilobar tumor 14 (7.0%) 25 (24.3%) 143 (21.0%) \0.001
Macrovascular invasion 19 (9.5%) 10 (9.7%) 80 (11.7%) 0.597
Microvascular invasion 35 (17.4%) 27 (26.2%) 212 (31.1%) \0.001
Perineural invasion 11 (5.5%) 26 (25.2%) 115 (16.9%) \0.001
Direct invasion of adjacent organs 7 (3.5%) 8 (7.8%) 57 (8.4%) 0.062
Satellite lesions 52 (25.9%) 22 (21.4%) 141 (20.7%) 0.297
AJCC T stage \0.001
T1-T2 188 (93.5%) 78 (75.7%) 483 (70.8%)
T3-T4 10 (5.0%) 20 (19.4%) 136 (19.9%)
Missing 3 (1.5%) 5 (4.9%) 63 (9.2%)
AJCC N stage \0.001
N0 167 (83.0%) 51 (49.5%) 323 (47.4%)
N1-N2 17 (8.5%) 23 (22.3%) 131 (19.2%)
Nx 17 (8.5%) 29 (28.2%) 228 (33.4%)
Histological grade \0.001
Well-to-moderate 184 (91.5%) 73 (70.9%) 522 (76.5%)
Poor to undifferentiated 13 (6.5%) 25 (24.2%) 130 (19.1%)
Missing 4 (2.0%) 5 (4.9%) 30 (4.4%)
Morphological type \0.001
Mass-forming 194 (96.5%) 83 (80.6%) 510 (74.8%)
Papillary 1 (0.5%) 7 (6.8%) 19 (2.8%)
Peri-ductal infiltrating 2 (1.0%) 3 (2.9%) 42 (6.2%)
Mass-forming ? peri-ductal infiltrating 4 (2.0%) 7 (6.8%) 57 (8.4%)
Missing 0 3 (2.9%) 54 (7.8%)
Resection procedure \0.001
Minor resection 157 (78.1%) 35 (34.0%) 202 (29.6%)
Major resection 44 (21.9%) 68 (66.0%) 480 (70.4%)
R0 resection 194 (96.5%) 83 (80.6%) 582 (85.3%) \0.001
Major vascular resection 16 (8.0%) 5 (4.9%) 100 (14.7%) 0.002
Lymphadenectomy 46 (22.9%) 64 (62.1%) 354 (51.9%) \0.001
Intraoperative blood loss 200.0 (150.0–475.0) 400.0 (250.0–900.0) 500.0 (250.0–900.0) \0.001
Operation time (min) 115.0 (90.0–150.0) 235.0 (163.5–360.0) 240.0 (171.0–364.8) \0.001
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Overall and recurrence-free survival
The OS and RFS following initial curative-intent surgery
are summarized in Fig. 1. Despite similarities in clinico-
pathologic factors, patients with stone-ICC had worse long-
term outcomes compared with patients who had conven-
tional ICC. In contrast, HBV-ICC patients had the best
outcomes. Specifically, 5-year RFS among HBV-ICC and
conventional ICC patients was 23.9% and 17.8%, respec-
tively, versus an RFS of only 8.3% among patients with
stone-ICC (all p\ 0.05) (Fig. 1a). Similarly, 5-year OS
among patients with stone-ICC was only 18.3% compared
with a 5-year OS of 48.9 and 38.0% for patients with HBV-
ICC and conventional ICC, respectively (Fig. 1b).
Given the differences in the baseline characteristics
among the groups, a 1:1 propensity score matching (PSM)
analysis was performed. Using PSM, 80 pairs of patients
who had stone-ICC and conventional ICC were identified
and matched on demographic data, presence of liver cir-
rhosis, tumor characteristics, as well as surgical margin and
perioperative morbidity (Supplementary Table 1). In the
propensity model, median RFS among stone-ICC and
conventional ICC patients were 12.0 months and
16.0 months, respectively; 5-year RFS was 7.8 and 26.6%,
respectively (p\ 0.01) (Fig. 2a). In examining OS,
patients with stone-ICC had a markedly shorter median OS
of 18.0 months versus 44.0 months for patients with con-
ventional ICC; similarly, 5-year OS was 17.8 and 44.4%,
respectively (p\ 0.01) (Fig. 2b).
PSM was also utilized to identify 41 pairs of patients
with stone-ICC and HBV-ICC who had comparable base-
line clinical and pathologic characteristics (Supplementary
Table 2). In the propensity model, patients with stone-ICC
had equivalent RFS and OS versus patients with HBV-ICC
(median RFS: 12.0 months vs 14.0 months; median OS:
21.0 months vs 27.0 months, both p[ 0.1, Figs. 2c and d).
Recurrence treatment and outcome
In total, 733 out of the 986 (74.3%) patients developed
tumor recurrence after the initial surgical resection. Among
patients who recurred, 476 (64.9%) had intrahepatic-only
Table 1 continued
HBV-ICC
(n = 201)
Stone-ICC
(n = 103)
Conventional ICC
(n = 682)
P value
Intraoperative blood transfusion 34 (16.9%) 39 (37.9%) 181 (26.5%) \0.001
Adjuvant chemo-/radio-therapy 17 (8.5%) 31 (30.1%) 255 (37.4%) \0.001
Postoperative complications \0.001
No complication 146 (72.6%) 55 (53.4%) 392 (57.5%)
Grade I–II 44 (21.9%) 22 (21.4%) 148 (21.7%)
Grade III–IV 8 (4.0%) 20 (19.4%) 106 (15.5%)
Grade V 3 (1.5%) 6 (5.8%) 36 (5.3%)
90-day mortality 8 (4.0%) 10 (9.7%) 41 (6.0%) 0.137
ICC intrahepatic cholangiocarcinoma, HBV hepatitis B virus, Ca19-9 Carbohydrate antigen 19-9, CEA Carcinoembryonic antigen, ALT alanine
aminotransferase, AST aspartate aminotransferase TBIL total bilirubin, AJCC American Joint Committee on Cancer
Fig. 1 Comparison of overall survival a and recurrence-free survival b after curative-intent surgery for HBV-ICC, stone-ICC and conventional
ICC. HBV, hepatitis B virus; ICC, intrahepatic cholangiocarcinoma; Con, conventional
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recurrence, while 89 (12.1%) and 168 (22.9%) experienced
an extrahepatic or combined intra- and extrahepatic
recurrence, respectively. Following the initial resection, the
timing and pattern of recurrence were no different among
patients who had HBV-ICC, stone-ICC, or conventional
ICC (both p[ 0.1, Fig. 3a and b). For patients with
intrahepatic-only recurrence, 115 (24.2%) patients under-
went curative-intent treatment of the recurrent tumor, while
269 (56.5%) and 92 (19.3%) patients received palliative
treatment or BSC, respectively. Notably, following resec-
tion of an initial HBV-ICC or stone-ICC, curative-intent
treatment of a recurrence was less common than treatment
of a conventional ICC recurrence (both p\ 0.001,
Fig. 3c). In turn, median OS after intrahepatic-only recur-
rence among patients who had stone-ICC (6.0 months) was
worse than OS among HBV-ICC (13.0 months) or con-
ventional ICC (12.0 months) (p = 0.006 and p = 0.082,
respectively, Fig. 4).
Discussion
Different etiologies of ICC may be related to varied and
distinct pathogenic mechanisms of disease. While a subset
of ICC tumors may be associated with a specific etiologic
factor (i.e. HBV, stones, etc.), most ICC tumors occur
sporadically without a known risk factor—which was
defined as conventional ICC in the present study [9, 10].
Predisposing factors such as chronic hepatitis viral infec-
tion and hepatolithiasis can be, however, important causes
of ICC in highly endemic areas [26]. The current study was
important because it defined the clinicopathological char-
acteristics, as well as prognosis, recurrence, and post-re-
currence outcomes of patients following curative-intent
resection stratified by HBV-ICC, stone-ICC, and conven-
tional ICC etiologic subtype. Of particular importance was
the inclusion of patients from a multi-institutional experi-
ence that included both patients from Western and Eastern
centers, as well as the use of PSM to compare patient
cohorts. Of note, HBV-ICC tumors had markedly different
clinicopathological characteristics compared with stone-
ICC or conventional ICC. In addition,
patients with stone-ICC had a markedly shorter median
OS compared with patients who had conventional ICC. In
contrast, on PSM, patients with stone-ICC had equivalent
RFS and OS versus patients who had HBV-ICC.
The finding that HBV-ICC patients were more likely
have cirrhosis was not unexpected, as chronic HBV
infection is a well-established risk factor for liver cirrhosis
[27, 28]. In fact, HBV-ICC may have a similar underlying
Fig. 2 Comparison of the overall survival and recurrence-free survival between stone-ICC and conventional ICC (a and b) and between HBV-
ICC and stone-ICC (c and d) after propensity score matching. HBV, hepatitis B virus; ICC, intrahepatic cholangiocarcinoma; Con,
conventional
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pathogenesis as HBV-associated HCC [28, 29]. Like HCC,
ICC can arise from any type of liver cell, including hepatic
precursor cells and adult hepatocytes [29, 30]. In turn,
HBV-HCC may be more likely to develop as a mass-
forming lesion rather demonstrates the intra- or peri-ductal
growth type, thereby emulating a histologically well-dif-
ferentiated HCC [29–33]. Interestingly, HBV-ICC was
more likely to present as an earlier stage tumor compared
with either stone-ICC or conventional ICC. Specifically,
HBV-ICC patients were less likely to have multiple
tumors, bilateral disease, and lymph node metastases.
HBV-ICC patients were also more likely have a mass-
forming ICC that was moderately differentiated—features
known to be associated with improved outcomes
[16, 34–36]. In turn, perhaps not surprisingly, patients with
HBV-ICC had better long-term outcomes compared with
other etiological causes of ICC on standard survival anal-
yses. However, after matching clinicopathological charac-
teristics on PSM, patients with HBV-ICC had a comparable
survival to patients who had stone-ICC. While the reasons
for this are undoubtedly multi-factorial, the data strongly
suggest that stage-for-stage survival of patients with HBV-
ICC versus stone-ICC was not different. Rather, the finding
that HBV patients had a better outcome on unadjusted
survival analysis may instead be related to earlier ICC
detection. This earlier detection may have been due to
more frequent standard surveillance typically performed
for patients with chronic liver disease.
Some previous studies had suggested that stone-ICC was
more often diagnosed at advanced stages due to difficulties
in differentiating this subtype of ICC from benign biliary
strictures [16]. Other studies, however, had reported
increased resectability for stone-ICC versus non-stone-ICC
due to earlier diagnosis secondary to the presence of hep-
atolithiasis-associated symptoms [37–39]. In the current
study, we noted that patients who had stone-ICC were
comparable to patients who presented with conventional
ICC and did not tend to present at later stages. Interest-
ingly, patients with stone-ICC were noted to have a worse
OS compared with patients who had conventional ICC both
before and after PSM. In addition, patients who developed
intrahepatic-only recurrence after initial surgery for stone-
ICC were unlikely to be candidates of second curative-
intent treatments for recurrent disease. In turn, stone-ICC
patients had a more dismal post-recurrence survival than
patients who experienced intrahepatic-only recurrence after
hepatic surgery for HBV-ICC or conventional ICC (Fig. 4).
These data would suggest that tumor biology, rather than
clinical characteristics, were contributing to the more
Fig. 3 The timing a, patterns b and treatments c of tumor
recurrence after initial curative surgery in HBV-ICC, stone-ICC
and conventional ICC groups. HBV, hepatitis B virus; ICC,
intrahepatic cholangiocarcinoma; Con, conventional
Fig. 4 Long-term survival calculated from the date of recurrence
among patients with HBV-ICC, stone-ICC and conventional ICC.
HBV, hepatitis B virus; ICC, intrahepatic cholangiocarcinoma; Con,
conventional
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aggressive nature of stone-ICC. Consistent with this
hypothesis, stone-ICC has been reported to have more
often a bile-duct pattern similar to hilar cholangiocarci-
noma [40]. Furthermore, HBV-ICC demonstrates less
KRAS mutations and more frequent IDH1 and IDH2
mutations, which are associated with DNA hypermethyla-
tion, prolonged time to recurrence, and improved survival
[41]. In contrast, activation of human epidermal growth
factor receptor 2 signaling has been more frequently
identified in stone-ICC, which might partially account for
the worse prognosis for this subtype of ICC [16, 42].
The current study had several limitations. The study
included many centers from around the world. While this
increased the generalizability of the study, certain factors
such as the indication for resection, nuances of surgical
technique, and perioperative management of patients
undoubtedly varied. In addition, data on the viral load and
antiviral treatments of patients with HBV-ICC were not
available. Moreover, while most ICC patients with an
unknown cause of ICC likely had a ‘‘sporadic’’ conven-
tional ICC, other possible etiologies of ICC such as PSC,
PBC, smoking, alcoholic, or nonalcoholic steatohepatitis
were not part of the database and therefore could not be
included in the analyses.
In conclusion, data from this large multi-institutional
study indicated that patients with HBV-ICC had more
favorable tumor features. While HBV-ICC had better RFS
and OS on unadjusted analyses, these differences were
mitigated on PSM suggesting no stage-for-stage differ-
ences in outcomes compared with stone-ICC or conven-
tional ICC. In contrast, while stone-ICC had similar tumor
characteristics with conventional ICC, patients with stone-
ICC had a worse RFS and OS. These data highlight the
relative importance of ICC etiology relative to established
clinicopathological factors in establishing the prognosis of
patients undergoing resection of ICC. Future studies will
need to define better the distinct underlying molecular
pathogenesis associated with the varied etiologies of ICC
to inform treatment and surveillance strategies.
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